Analysis of KRAS gene mutation associated with Helicobacter pylori infection in patients with gastric cancer

Document Type : Original Article


1 Biotechnology Research Center, Pharmaceutical technology institute, Mashhad University of Medical Sciences, Mashhad, Iran

2 Gastroenterology and Hepatology Specialist, Mashhad, Iran

3 Pathology Department of Hematology and Blood Banking, Cancer Molecular Pathology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

4 Gastroenterology and Hepatology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran


Objective(s): KRAS proto-oncogene mutation can be considered a diagnostic factor for treating various malignancies. Helicobacter pylori infection, a risk factor for stomach cancer, may cause DNA damage and genetic changes. The aim of the current study was to assess the association of gastric cancer and KRAS mutation, demographic factors, and H. pylori infection.
Materials and Methods: DNA was extracted from a total of 140 FFPE gastric cancer tissue samples. detection of KRAS mutation (codons 12 and 13) in tumors was performed by PCR amplification, followed by gel electrophoresis and DNA sequencing. PCR diagnosed any H. pylori infection.
Results: KRAS mutation was detected in 6 of the 140 (4.2%) gastric cancer tissue samples. 18 samples (12.8%), all of which were male (P<0.05), tested positive for H. pylori infection. KRAS mutations were present in 22.2% (4/18) of the samples with H. pylori infection (P<0.05). The mean age of patients was 62.25±12.61 years (range: 30–93 years). A male predominance (2.5 to 1) was reported in the gastric cancers, and at diagnosis, women were significantly younger than men (P=0.004). No association was observed between age or gender and KRAS mutation. Neither was one found between age and H. pylori infection. Tumors from H. pylori+ subjects were significantly more likely to have KRAS mutation than tumors from H. pylori- subjects (OR=17.1).
Conclusion: The data suggest that H. pylori infection when compared with the absence of H. pylori infection, is associated with a higher prevalence of KRAS mutation in gastric cancer.


Main Subjects

1. Jiang B, Li S, Jiang Z, Shao P. Gastric cancer associated genes identified by an integrative analysis of gene expression data. Biomed Res Int 2017;2017:7259097.
2. Shibata A, Parsonnet J, Longacre TA, Garcia MI, Puligandla B, Davis RE, et al. CagA status of Helicobacter pylori infection and p53 gene mutations in gastric adenocarcinoma. Carcinogenesis 2002; 23: 419-424.
3. Amoori N, Mahdavi S, Enayatrad M. Epidemiology and trend of stomach cancer mortality in Iran (2006-10). Int J Epidemiol Res 2016; 3: 268-275.
4. Hiyama T, Haruma K, Kitadai Y, Masuda H, Miyamoto M, Tanaka S, et al. K‐ras mutation in Helicobacter pylori‐associated chronic gastritis in patients with and without gastric cancer. Int J Cancer 2002; 97: 562-566.
5. Do H, Krypuy M, Mitchell PL, Fox SB, Dobrovic A. High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC cancer 2008; 8: 142-156.
6. Hamzehzadeh L, khadangi F, Ghayoor Karimiani E, Pasdar A, Kerachian MA. Common KRAS and NRAS gene mutation in sporadic colorectal cancer in Northeastern Iranian patients. Curr Probl Cancer 2018; 4:572-581.
7. Castagnola P, Giaretti W. Mutant KRAS, chromosomal instability and prognosis in colorectal cancer. Biochim Biophys Acta 2005; 1756: 115-125.
8. Furukawa T, Sunamura M, Horii A. Molecular mechanisms of pancreatic carcinogenesis. Cancer Sci 2006; 97: 1-7.
9. Karachaliou N, Mayo C, Costa C, Magrí I, Gimenez-Capitan A, Molina-Vila MA, et al.  KRAS mutations in lung cancer. Clin Lung Cancer 2013; 14: 205-214.
10. Sepulveda AR. Helicobacter, inflammation, and gastric cancer. Curr Pathobiol Rep 2013; 1: 9-18.
11. Saghier AA, Kabanja JH, Afreen S, Sagar M. Gastric cancer: Environmental risk factors, treatment and prevention. J Carcinogene Mutagene 2013.
12. Rugge M, Fassan M,Graham DY. Epidemiology of gastric cancer. In: Strong VE, editor. Gastric Cancer: Principles and Practice. 2015 ed. Springer International Publishing; 2015.p. 23-34.
13. Zarea K, Beiranvand S, Ghanbari S,Tuvesson H. Incidence of gastrointestinal cancers in Iran: A Systematic Review. Jundishapur J Chronic Dis Care 2017; 1-7.
14. Nardone G. Molecular basis of gastric carcinogenesis. Aliment Pharmacol Ther 2003; 17: 75-81.
15. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A,Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006; 24: 2903-2909.
16. Chen C, Köberle B, Kaufmann AM, Albers AE. A quest for initiating cells of head and neck cancer and their treatment. Cancers 2010; 2: 1528-1554.
17. Jabini R, Moradi A, Afsharnezhad S, Ayatollahi H, Behravan J, Raziee HR, et al. Pathodiagnostic parameters and evaluation of O 6–methyl guanine methyl transferase gene promoter methylation in meningiomas. Gene 2014; 538: 348-353.
18. Ebrahimian M, Taghavi S, Ghoreishi M, Sedghi S, Farzad S A, Ramezani M, et al. Evaluation of efficiency of modified polypropylenimine (PPI) with alkyl Chains as non-viral vectors used in co-delivery of doxorubicin and TRAIL plasmid. AAPS Pharm Sci Tech 2018; 19: 1029-1036.
19. Farzanehfar M, Vossoughinia H, Jabini R, Tavassoli A, Saadatnia H, Khorashad A K, et al. Evaluation of methylation of MGMT (O6-methylguanine-DNA methyltransferase) gene promoter in sporadic colorectal cancer. DNA Cell Biol 2013; 32: 371-377.
20. Fernández-Medarde A, Santos E. Ras in cancer and developmental diseases. Genes Cancer 2011; 2: 344-358.
21. Vakiani E, Solit DB. KRAS and BRAF: drug targets and predictive biomarkers. J Pathol 2011; 223: 219-229.
22. Amado R G, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman D J, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-1634.
23. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66: 3992-3995. 24. Van Grieken NC, Aoyma T, Chambers PA, Bottomley D, Ward LC, Inam I, et al. KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: results from a large international multicentre study. Br J Cancer 2013; 108: 1495-1501.
25. Ishaq S, Nunn L. Helicobacter pylori and gastric cancer: a state of the art review. Gastroenterol Hepatol Bed Bench 2015; 8: S6-S14.
26. Khadangi F, Yassi M, kerachian MA. Diagnostic accuracy of PCR-based detection test for Helicobacter pylori in stool samples: A systematic review and meta-analysis. Helicobacter 2017; 22: e12444.
27. Neugut AI, Hayek M, Howe G. Epidemiology of gastric cancer. Semin Oncol 1996; 23: 281-291.
28. Towensend CMJR,  Beauchamp RD. Stomach. In: Townsend CM, editor. Sabistone Textbook of Surgery. 16 th ed. Amazon; 2001.
29. Bos JL, Vries MVd, Marshall CJ, Veeneman GH, Van Boom JH, Van der EbAJ. A human gastric carcinoma contains a single mutated and an amplified normal allele of the Ki-ras oncogene. Nucleic Acids Res 1986; 14: 1209-1217.
30. Victor T, Du Toit R, Jordaan AM, Bester AJ, Van Helden PD. No evidence for point mutations in codons 12, 13, and 61 of the ras gene in a high-incidence area for esophageal and gastric cancers. Cancer Res1990; 50: 4911-4914.
31. Saxena A, Shukla SK, Prasad KN, Ghoshal UC. Analysis of p53, K-ras gene mutation & Helicobacter pylori infection in patients with gastric cancer & peptic ulcer disease at a tertiary care hospital in North India. Indian J Med Res 2012; 136: 664-670.
32. Mita H, Toyota M, Aoki F, Akashi H, Maruyama R, Sasaki Y, et al. A novel method, digital genome scanning detects KRAS gene amplification in gastric cancers: involvement of overexpressed wild-type KRAS in downstream signaling and cancer cell growth. BMC Cancer 2009; 9: 198-214.
33. Craanen ME, Blok P, Top B, Boerrigter L, Dekker W, Offerhaus GJ, et al. Absence of ras gene mutations in early gastric carcinomas. Gut 1995; 37: 758-762.
34. Hongyo T, Buzard GS, Palli D, Weghorst CM, Amorosi A, Galli M, et al. Mutations of the K-ras and p53 genes in gastric adenocarcinomas from a high-incidence region around Florence, Italy. Cancer Res 1995; 55: 2665-2672.
35. Miki H, Ohmori M, Perantoni AO, Enomoto T. K-ras activation in gastric epithelial tumors in Japanese. Cancer Lett 1991; 58: 107-113.
36. Corso G, Velho S, Paredes J, Pedrazzani C, Martins D, Milanezi F, et al. Oncogenic mutations in gastric cancer with microsatellite instability. Eur J Cancer 2011; 47: 443-451. 37. Anderson S M. Laboratory methods for KRAS mutation analysis. Expert Rev Mol Diagn 2011; 11: 635-642.
38. Nejat M, Rabbani B. An overview of mutation detection methods in genetic disorders. Iran J Pediatr. 2013; 23: 375-388.
39. Sasao S, Hiyama T, Tanaka S, Yoshihara M, Yasui W, Chayama K. Clinicopathologic and genetic characteristics of gastric cancer in young male and female patients. Oncol Rep 2006; 16: 11-15.
40. Zhu Y, Zhou X, Wu J, Su J, Zhang G. Risk factors and prevalence of Helicobacter pylori infection in persistent high incidence area of gastric carcinoma in Yangzhong city. Gastroenterol Res Pract 2014.
41. Agah S, Khedmat H, Ghamar-Chehred M E, Hadi R, Aghaei A. Female gender and Helicobacter pylori infection, the most important predisposition factors in a cohort of gastric cancer: A longitudinal study. Caspian J Intern Med 2016;7: 136-141
42. Chey WD, Lontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori infection. Am J Gastroenterol 2017; 112: 232-238.
43. Mastromatteo P, Correnti M, Cavazza ME, Perrone M, Tombazzi C, Lecuna V. Evaluation of K-ras 12 oncogene mutations in Venezuelan patients with Helicobacter pylori infection. Invest Clin 2005; 46:337-345.
44. Watari J, Tanaka A, Tanabe H, Sato R, Moriichi K, Zaky A, et al. K-ras mutations and cell kinetics in Helicobacter pylori associated gastric intestinal metaplasia: a comparison before and after eradication in patients with chronic gastritis and gastric cancer. J Clin Pathol 2007; 60: 921-926.       
45. Tornesello ML, Buonaguro L, Tatangelo F, Botti G, Izzo F, Buonaguro FM. Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections. Genomics 2013; 102: 74-83.